Anemias

FDA Approves Epoetin Alfa Biosimilar Retacrit

By May 15, 2018

The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.

Sickle cell trait not linked to increased risk of ischemic stroke

April 27, 2018

In this meta-analysis of prospective population-based studies, sickle cell trait (SCT) was not associated with any difference in risk of first ischemic stroke.

IBD and Anemia: Adverse Events After IV Iron Therapy Examined

By April 23, 2018

To examine the occurrence of adverse reactions in this patient population, researchers from John Hopkins University, Baltimore, Maryland, conducted a retrospective analysis of IBD patients who received IV iron infusions between 2010 and 2014 in the commercial claims database, MarketScan.

Iron Formulation and Cancer Risk: Is There a Link?

By April 12, 2018

In the U.S., ferric citrate is commonly found in dietary supplements and ferric EDTA is often used as a food additive.

Oral vs. Intramuscular Vitamin B<sub>12</sub>: Efficacy, Safety Compared

By March 16, 2018

Researchers from Beijing University of Chinese Medicine and the Catalan Health Institute, Spain sought to investigate the effects of oral vitamin B12 vs. IM vitamin B12 to determine whether outcomes for vitamin B12 deficient patients would differ based on the formulation.

Antibiotic Prophylaxis Rates Low for Pediatric Sickle Cell Patients

February 06, 2018

Data were included for 2,821 children with 5,014 person-years. The researchers found that 18 percent of children received ≥300 days of antibiotics.

FDA Approves Expanded Use for Feraheme in Iron Deficiency Anemia

By February 05, 2018

The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.

Iron Dextran Injection Recall Expanded

By January 25, 2018

The recall was initiated due to product stability testing results that did not meet specifications for iron content.

Treating a Common Extraintestinal Manifestation of Inflammatory Bowel Disease

January 05, 2018

Mr. C, a 30-year-old male with Crohn's disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.

Iron Deficiency Treatment in a Heart Failure Patient

December 11, 2017

A women with a 30-year history of hypertension, hyperlipidemia and an 8-year history of systolic dysfunction is hospitalized for congestion following a 5-day river cruise.

Possible New Marker of Kidney Disease Identified in Sickle Cell

December 05, 2017

Subsequently, 18 extracellular proteins were focused on, including CP, a protein involved in iron metabolism.

Incidence of Adverse Events Compared Among IV Iron Compounds

By December 04, 2017

It was also found that fewer all-cause ED visits or hospitalizations occurred in non-CKD patients (HR: 0.56; 95% CI: 0.45, 0.70) as well as in NDD-CKD patients (HR: 0.83; 95% CI: 0.71, 0.95) treated with ferumoxytol.

IV Iron Sucrose Evaluated for Iron Deficiency Anemia in Pediatric IBD

By December 01, 2017

Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions).

Ferric Carboxymaltose Tx Examined in Chronic HF Patients With Iron Deficiency

By December 01, 2017

Results demonstrated that both serum ferritin as well as transferrin saturation were significantly increased after FCM administration.

Frequency of Celiac Disease Testing Examined in Patients with IDA

By November 30, 2017

The subgroup that was most frequently tested was young Caucasian men, with 61% of respondents stating that they would implement serologic testing in this group.

Treating Iron Deficiency Anemia in Patients With Heart Failure

By November 16, 2017

To shed light on the often-challenging management of this common condition, MPR presented the case of a hypothetical patient to a doctor who specializes in advanced heart failure and transplant cardiology.

Auryxia Approved for Iron Deficiency Anemia in Patients With CKD

By November 07, 2017

At any point during the 16-week efficacy period, 52.1% (n=61/117) of the Auryxia treated group demonstrated hemoglobin levels of ≥1g/dL compared to 19.1% (n=22/115) of the placebo group.

Lenalidomide Assessed for Hematologic Response in Patients With MDS/MPN-RS-T

November 01, 2017

"While lenalidomide therapy does produce hematological responses in patients with MDS/MPN-RS-T, these are often suboptimal, without significant changes in bone marrow morphology," the authors found.

Treating Iron Deficiency Anemia in Patients With Inflammatory Bowl Disorder

By October 19, 2017

Despite its frequency, iron deficiency anemia in patients with IBD it is often overlooked in clinical settings.

Recall of Erythropoiesis-Stimulating Agent Expanded

By September 26, 2017

The recall is due to the finding of glass flakes (lamellae) observed in 2 additional Lots during a routine inspection.

Aplastic Anemia Outcomes Examined for Anti-Thymoglobulin-Based IST

September 07, 2017

The researchers found that OS was superior in IST responders. Shorter relapse-free survival (RFS) was seen with partial response to IST compared with complete response.

ESA Agent Recalled Due to Presence of Particulate in Vials

By August 22, 2017

Healthcare professionals are urged to following the package insert instructions regarding careful inspection of vials.

Eculizumab Linked to High Risk of Meningococcal Disease, Despite Vaccination

By July 10, 2017

In vitro data have shown that eculizumab impairs meningococcal killing in whole blood despite patients being vaccinated against the appropriate serogroup. The current vaccines against meningococcal disease only target serogroup-specific proteins and do not provide protection against nongroupable N. meningitidis.

Breckenridge Approved for Generic Vidaza

By June 29, 2017

Vidaza is indicated as treatment for myelodysplastic syndrome (MDS), specifically refractory anemias and chronic myelomonocytic leukemia; it can be given either subcutaneously (SC) or intravenously (IV).

Ferrous Sulfate vs. Iron Polysaccharide in Iron-Deficient Anemic Infants

June 14, 2017

The researchers found that the mean hemoglobin increased from 7.9 to 11.9 g/dL in the ferrous sulfate group, compared with 7.7 to 11.1 g/dL in the iron polysaccharide complex group (greater difference of 1.0 g/dL with ferrous sulfate).

First ESA Biosimilar Gets FDA Advisory Committee Nod

By May 26, 2017

The FDA will consider the Committee's recommendation before acting on the biologics license application (BLA) for the epoetin alfa biosimilar.

FDA Committee Votes in Favor of Endari for Sickle Cell Disease

By May 25, 2017

An efficacy study of L-glutamine (Study 09-01) showed that the treatment resulted in a lower frequency of sickle cell painful crises, longer time to first and second crisis compared to placebo.

FDA: Prescribing Change for ESAs

By April 13, 2017

The decision was made based on data which showed that clinicians demonstrated acceptable knowledge of the product risks.

Stem Cell Transplant Cures First Adult Patient of Rare Blood Disorder

By March 21, 2017

The patient underwent a non-myeloablative (NMA) peripheral blood stem cell transplant from a 10/10 HLA Ag matched, ABO incompatible unrelated donor.

Warm Autoimmune Hemolytic Anemia Occurs After Babesiosis

March 10, 2017

The researchers documented warm autoimmune hemolytic anemia following babesiosis in patients with no history of autimmunity, they said there was no alternative explanation for clinical hemolysis.